PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Demand for Therapies to Treat Drug Resistant HIV Strains is Increasing Finds Frost & Sullivan - The HIV/AIDS market in Europe faces a number of hurdles in the form of late diagnosis and low awareness levels
Demand for Therapies to Treat Drug Resistant HIV Strains is Increasing Finds Frost & Sullivan

 

NewswireToday - /newswire/ - London, United Kingdom, 2009/09/28 - The HIV/AIDS market in Europe faces a number of hurdles in the form of late diagnosis and low awareness levels.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

However, the market is projected to exhibit strong growth due to the introduction of novel drug classes and increasing efforts to achieve high diagnosis rates.

New analysis from Frost & Sullivan (pharma.frost.com), European HIV/AIDS Therapeutics Markets, finds that the markets earned revenues of $3.88 billion in 2008 and estimates this to reach $6.79 billion in 2015.

"Market growth will be spurred by the new drug classes and combination therapies introduced recently," notes Sylvia M. Findlay, programme manager Pharmaceuticals & Biotechnology from Frost & Sullivan. "Novel drug classes which treat drug resistant HIV strains are expected to be used in combination with first-line therapy in experienced patients. Combination therapies which minimise side-effects and pill burden are supporting market development."

New drug classes are being researched and introduced into the market, especially targeting experienced patients. These drugs are being tested in clinical trials for use in combination with established first-line therapies and also as first-line therapies themselves. Proving the long-term safety and efficacy of these drugs is anticipated to boost their uptake and revenues.

Europe is already at a disadvantage because of the ban on direct-to-consumer marketing. Moreover, the launch and subsequent uptake of drugs is slower than in the US market. Social stigma and discrimination associated with HIV/AIDS, especially in Eastern Europe, is further limiting the growth potential of the market.

"Europe is a very diverse market where epidemiology, regulations and awareness levels vary considerably," explains Miss Findlay. "The level of adherence to recommended therapy regimens varies across the region, largely due to the lack of awareness about the safety and efficacy profiles of drugs used."

Moreover, diagnoses rates, which are influenced by awareness and societal pressures, vary across the region. This demands the formulation of region-specific strategies to promote market growth.

Companies need to update their knowledge of epidemiology, promote adherence to recommended therapies and enhance awareness on a continuous basis. They need to devise strategies to address challenges that impede the growth of their product portfolio. Market participants should use prescription trends to assess the market potential for their drugs, both as a first-line and a second-line therapy.

"Physicians are the sole point of contact for patients in Europe, given the absence of direct-to-consumer marketing," says Miss Findlay. "Analysing prescription trends and patients' perception towards new drugs as well as the drugs they are currently using is imperative to maintain patient base."

European HIV/AIDS Therapeutics Markets covers nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors, protease inhibitors and fusion inhibitors. The research service is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: European Therapeutic Monoclonal Antibody Markets, European Pharma/Biotech Contract Manufacturing Markets: A Strategic Outlook, European Human Growth Hormones Market and, European Drug Delivery Markets - Opportunity Analysis. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Katja Feick, Corporate Communications, at katja.feick[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by email.

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents.

European HIV/AIDS Therapeutics Markets / M335

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Demand for Therapies to Treat Drug Resistant HIV Strains is Increasing Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Katja Feick 
+49 (0) 69 7703343 katja.feick[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  SKS Media | SKS Associates Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)